Life Science News

RSS

MP receives FDA IND approval for clinical trial with HTLV-I/II ELISA 4.0 and HTLV Blot.2.4

MP Biomedicals LLC announced today that it has received approval of its investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to start pivotal clinical trials in the USA with the MP Diagnostics™ HTLV-I/II ELISA 4.0 and HTLV Blot.2.4. Studies will be conducted within the American Red Cross, the California Department of Public Health, and LABS, Inc. The company is working closely with the principal investigator of the American Red Cross sites, Dr. Susan Stramer, Executive Scientific Officer.

From MP Biomedicals, LLC 7 Dec 2010

Olympus PlasmaButton- vaporization technology now usable with Gyrus ACMI SuperPulse- Generator platform

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products among other core businesses, announced today that its revolutionary PlasmaButton- vaporization technology can now be used with the Gyrus ACMI SuperPulse- Generator platform. Together, the PlasmaButton electrode and SuperPulse Generator provide physicians and patients with a new, virtually bloodless treatment option for benign prostate hyperplasia (BPH) or enlarged prostate.

From Evident Corporation - Life Sciences 3 Dec 2010

$Bruker’s AcuityXR with ContourGT optical surface profilers break diffraction limit$

Bruker’s AcuityXR with ContourGT optical surface profilers break diffraction limit

Bruker Corporation announced today at the Materials Research Society (MRS) Fall 2010 Meeting the AcuityXR™, a novel optical surface profiler mode that combines unique, patent-pending Bruker hardware and software technology to enable select ContourGT™ non-contact, 3D optical surface profilers to break the optical diffraction limit and deliver lateral resolutions that were previously considered impossible to achieve.

From Bruker Nano Surfaces and Metrology 30 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

BioNeutral signs 'Stand Still' agreement with DFB

BioNeutral Group, Inc., a specialty technology-based life science company, today announced it has signed a "Stand Still" agreement with a leading pharmaceutical company, DFB Pharmaceuticals, Inc. (DFB).

From Evident Corporation - Life Sciences 22 Nov 2010

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death

From Roche Sequencing and Life Science 17 Nov 2010

Roche, CapitalBio to initiate strategic partnership for molecular diagnostic applications

Roche Diagnostics and CapitalBio have announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. This new development builds on the genomics and diagnostics expertise of the two companies and will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

From Roche Sequencing and Life Science 11 Nov 2010

Illumina launches TruSeq sample preparation, Exome Enrichment kits for sequencing studies

Illumina, Inc. today announced TruSeq sample preparation kits for DNA, RNA, and small RNA applications and the TruSeq Exome Enrichment Kit, for use across the company's portfolio of sequencing platforms.

From Illumina, Inc. 3 Nov 2010

Illumina, Expression Analysis support Cancer GWAS and Data Analysis Grant program

Expression Analysis today announced that it and Illumina, Inc. are jointly funding a Cancer GWAS (Genome-Wide Association Study) and Data Analysis Grant program to support cutting-edge projects that show promise in identifying genetic elements important to cancer research and treatment.

From Illumina, Inc. 3 Nov 2010

Roche announces U.S. introduction of cobas e 602 analyzer

Roche announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs will now be able to combine this new immunoassay module with two existing clinical chemistry modules to create an integrated platform with 24 unique system configurations to match their specific testing needs.

From Roche Sequencing and Life Science 30 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Thermo Fisher 2010 third quarter revenue increases 6% to $2.68 billion

Thermo Fisher Scientific Inc. the world leader in serving science, today reported financial results for the third quarter ended October 2, 2010.

From Thermo Fisher Scientific Inc. 27 Oct 2010

Illumina announces single flow cell version of HiSeq 2000 sequencing system

Illumina, Inc. today announced HiSeq 1000, a single flow cell version of the company's HiSeq 2000 sequencing system. HiSeq 1000 is designed for researchers who want the ease of use, industry-leading cost per gigabase (Gb) and data rate of the HiSeq 2000 but do not currently require its throughput. As their research scales, users will be able to upgrade their system to the HiSeq 2000 and double their output.

From Illumina, Inc. 27 Oct 2010

Illumina 2010 third quarter revenue increases 50% to $237.3 million

Illumina, Inc. today announced its financial results for the third quarter of 2010.

From Illumina, Inc. 27 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

Panasonic completes investment in CardioNexus

Panasonic Corporation of North America has completed an investment in CardioNexus Corporation, a portfolio company of Houston's Fairway Medical Technologies which works closely with the Texas Medical Center. The move is part of Panasonic's plans to establish itself as a global leader in Personalized Preventive Medicine. The investment follows on an earlier Panasonic initiative to establish a presence in the world's largest medical complex, the Texas Medical Center based in Houston.

From PHC Europe B.V. 26 Oct 2010

Helicos names Illumina and Life Technologies as additional defendants in lawsuit against Pacific Biosciences

Helicos BioSciences Corporation announced today that it has amended its lawsuit against Pacific Biosciences of California, Inc. for patent infringement by naming Illumina, Inc. and Life Technologies Corporation as additional defendants.

From Illumina, Inc. 25 Oct 2010

Tecan, Luminex collaborate to develop automated newborn screening solution

The Tecan Group and Luminex Corporation have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns.

From Tecan 13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

Roche, DKFZ announce research collaboration to predict cervical cancer risk

Roche Molecular Systems, Inc. and the German Cancer Research Center announced today that they have entered into a research collaboration to enable more specific prediction of a woman's risk for developing cervical cancer.

From Roche Sequencing and Life Science 11 Oct 2010